ArticleBMC immunology2026
Saussurea involucrata oral liquid alleviates joint inflammation in CIA rats by modulating macrophage polarization and glucose metabolism.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo evaluate the therapeutic effects of Saussurea involucrata Oral Liquid (SIOL) in a collagen-induced arthritis (CIA) rat model.
methodsThis study was conducted from April 2023 to June 2024. Sixty male SPF SD rats were randomly divided into six groups: control, model, tripterygium glycosides tablet (TGT) group, and low, medium, and high doses of SIOL. CIA was induced by subcutaneous injection of bovine type II collagen (CII) and incomplete Freund’s adjuvant (IFA). Treatment groups received corresponding doses of SIOL or TGT. Therapeutic efficacy was assessed through body weight, arthritis index (AI), ankle diameter, and toe volume. Joint tissue pathology, serum and synovial inflammatory factors, macrophage polarization, and plasma metabolites were analyzed using H&E staining, ELISA, flow cytometry, Western blotting, and LC–MS.
resultsSIOL significantly reduced AI, ankle diameter, toe volume, and pathological scores compared to the model group. SIOL also decreased serum and synovial proinflammatory factors TNF-α, IL-6, and IL-1β while increasing anti-inflammatory IL-10 and IL-4. Medium and high doses of SIOL notably lowered M1 macrophage markers CD86 and iNOS, while elevating M2 markers CD163 and Arg-1. No significant differences were observed between the medium/high SIOL and TGT groups regarding therapeutic effects. Additionally, SIOL (high dose) markedly reduced glucose metabolism-related plasma metabolites, particularly key metabolites in the TCA cycle. A significant correlation was found between macrophage polarization, inflammatory markers, and metabolite levels.
conclusionSIOL alleviates joint inflammation in CIA rats, which is associated with modulation of macrophage polarization and alterations in glucose metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.